Moderna Inc

NASDAQ: MRNA
$121.14
-$0.18 (-0.1%)
Closing Price on July 19, 2024

MRNA Chart and Intraday Price

MRNA Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 36,319.86M USD
Shares Outstanding 382,073,000
Moderna Inc is a pioneering biotechnology firm based in Cambridge, Massachusetts, known for its innovative use of messenger RNA (mRNA) to develop vaccines and therapeutics. The company has made significant strides in addressing infectious diseases, including COVID-19, influenza, and more, as well as tackling challenges in immuno-oncology, rare diseases, autoimmune disorders, and cardiovascular diseases. Moderna's portfolio includes both respiratory and latent vaccines, public health vaccines, and treatments for infectious diseases. Additionally, it focuses on systemic secreted, cell surface therapeutics, cancer vaccines, and inhaled pulmonary therapeutics, supported by strategic alliances with global pharmaceutical leaders and research organizations.

MRNA Articles

 Invesco QQQ Trust (NASDAQ: QQQ) is an ETF that tracks the performance of the 100 largest companies listed on the Nasdaq. While this is mainly made up of technology companies, it holds the stocks in...
With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%. Therefore, sustainable dividend income and capital...
Analysts have been cutting ratings and price targets recently, but here are four stocks that defying the downward pressure.
2018 was one of the last full years we would feel normal as a world for a long time. We had no idea what was hurling around the corner. That year, Drake led the charts with “God’s Plan” and...
U.S. stocks are adding to Wednesday's comeback with solid gains after about half an hour of trading Thursday morning. Here are winners and losers.
Pfizer stock has tumbled due to shrinking vaccine sales and the potential for a social and consumer backlash. Moderna stock has also been pounded.
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange,...
Friday's top analyst upgrades and downgrades included DXC Technology, Etsy, Extreme Networks, Moderna, PagSeguro Digital, Qualcomm, Roku, Ross Stores, Royal Caribbean Cruises, Southwest Airlines,...
Monday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Accenture, Clorox, Fiserv, Moderna, Planet Fitness, Sarepta Therapeutics, Tesla, Under Armour, Ventas, Viatris,...
Tuesday's top analyst upgrades and downgrades included Agilon Health, Boston Scientific, General Motors, JPMorgan Chase, Match, Moderna, Okta, Palo Alto Networks, Snap, Uber Technologies and Wells...
Wednesday morning's report on the consumer price index likely will set the direction for stock traders. But there are some outliers.
Tuesday's top analyst upgrades and downgrades included Ally Financial, Amgen, Baidu, Bilibili, Bill.com, Coinbase Global, Eli Lilly, GE Healthcare Technologies, JPMorgan Chase, Merck, Moderna,...
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Apple, Array Technologies, CarMax, Coupang, Discover Financial Services, Intel, Kohl's, Marvell Technology, Moderna, Nio,...
Monday's top analyst upgrades and downgrades included Block, Broadcom, CarMax, Deere, Esperion Therapeutics, Marvell Technology, MGM Resorts International, Moderna, Newmont, Vipshop and Wingstop.